Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Ren, Liqun ^a   Liu, Naifeng ^a   Zhi, Hong ^a   Li, Yingjuan ^a   Li, Yanzhi ^a   Tang, Rining ^a   Sheng, Zulong ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METHYLTHIOURACIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CARDIOVASCULAR AGENT; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; AORTA INTIMA; ARTICLE; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL DIET; COLORIMETRY; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID STORAGE; MALE; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; AORTA DISEASE; ATHEROSCLEROSIS; BLOOD; DISEASE MODEL; DOSE RESPONSE; DRUG POTENTIATION; GENETICS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; AORTIC DISEASES; ATHEROSCLEROSIS; BLOTTING, WESTERN; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPIDS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PPAR GAMMA; RADIOIMMUNOASSAY; RATS; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 79251539250     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-10     Document Type: Article

References (50)

1. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000, 2:327-335. 10.1007/s11883-000-0067-3, 11122762.
2. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10K-15K. 10.1016/S0002-9149(01)01924-5, 11694213.
3. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235-238.
4. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710. 10.1161/01.RES.0000014225.20727.8F, 11934839.
5. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-fgammag agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 106:3126-3132. 10.1161/01.CIR.0000039346.31538.2C, 12473562.
6. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator- activated receptor-gamma ligand, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003, 83:1715-1721. 10.1097/01.LAB.0000106724.29121.DA, 14691289.
7. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor- gamma agonist rosiglitazone. Circulation 2001, 104:2588-2594. 10.1161/hc4601.099403, 11714655.
8. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 2004, 62:135-144. 10.1016/j.cardiores.2003.12.027, 15023560.
9. Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 2002, 103(Suppl 48):16S-20S.
10. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Atherioscler Thromb Vasc Biol 2001, 21:365-371.
11. Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 2002, 33:1026-1036. 10.1016/S0891-5849(02)01015-8, 12374614.
12. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002, 323:17-24. 10.1097/00000441-200201000-00004, 11814137.
13. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997, 95:473-478.
14. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
15. Wassmann S, Czech T, van Eickels M, Fleming I, Böhm M, Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004, 110:3062-3067. 10.1161/01.CIR.0000137970.47771.AF, 15277329.
16. Hu Q, Zhang Y, Zhang XJ. Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein- knock out mice. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:1050-1056.
17. Tarchalski J, Guzik P, Wysocki H. Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 2003, 246:25-30. 10.1023/A:1023443609730, 12841339.
18. Yamashita S, Nakamura M, Koizumi H, Oku H, Sandoval JC, Tsubakio-Yamamoto K, Kawase M, Masuda D, Koseki M, Matsuura F, Shimomura I, Nishida M, Ishigami M. Evaluation of a homogeneous assay for measuring LDL-cholesterol in hyperlipidemic serum specimens. J Atheroscler Thromb 2008, 15:82-86.
19. Bradford MM. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
20. Goetze S, Kintscher U, Kawano H, Kawano Y, Wakino S, Fleck E, Hsueh WA, Law RE. Tumor necrosis factor-α inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2000, 275:18279-18283. 10.1074/jbc.M909795199, 10764814.
21. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPARγ Activation Prevents Hypertensive Remodeling of Cerebral Arteries and Improves Vascular Function in Female Rats. Stroke 2010, 41:1266-1270. 10.1161/STROKEAHA.109.576942, 20395611.
22. Foryst-Ludwig A, Hartge M, Clemenz M, Sprang C, Hess K, Marx N, Unger T, Kintscher U. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol 2010, 9:64. 10.1186/1475-2840-9-64, 2984486, 20955583.
23. Lee JW, Nam-Goong IS, Kim JG, Yun CH, Kim SJ, Choi JI, Kim YI, Kim ES. Effects of Rosiglitazone on Inflammation in Otsuka Long-Evans Tokushima Fatty Rats. Korean Diabetes J 2010, 34:191-9. 10.4093/kdj.2010.34.3.191, 2898933, 20617080.
24. Lu X, Guo X, Karathanasis SK, Zimmerman KM, Onyia JE, Peterson RG, Kassab GS. Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 2010, 9:19. 10.1186/1475-2840-9-19, 2891691, 20482873.
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761, 17517853.
26. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195. 10.1001/jama.298.10.1189, 17848653.
27. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeid M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes inpatients with impaired glucose tolerance or impaired fasting glucose: arandomised controlled trial. Lancet 2006, 368:1096-1105. 10.1016/S0140-6736(06)69829-2, 16997664.
28. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, . for the ADOPT Study Group Glycemicdurability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. 10.1056/NEJMoa066224, 17145742, for the ADOPT Study Group.
29. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, . RECORD Study group Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007, 357:28-38. 10.1056/NEJMoa073394, 17551159, RECORD Study group.
30. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097-1103.
31. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
32. Hsueh WA, Law RE. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001, 21:1891-1895. 10.1161/hq1201.100261, 11742860.
33. Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin. North Am 2006, 35:561-574. ix, 10.1016/j.ecl.2006.06.001, 16959586.
34. Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator- activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 2006, 6:231-242.
35. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholes -terolemia. Circulation 2003, 108:2805-2811. 10.1161/01.CIR.0000097003.49585.5E, 14610009.
36. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996, 226:862-868. 10.1006/bbrc.1996.1441, 8831702.
37. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999, 33:335-339.
38. Lund DD, Brooks RM, Faraci FM, Heistad DD. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 2007, 293:H3726-3731. 10.1152/ajpheart.01116.2007, 17965276.
39. Benkirane K, Amiri F, Diep QN, EI Mabrouk M, Schiffrin EL. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 2006, 290:H390-397. 10.1152/ajpheart.00662.2005, 16155101.
40. Fukuda N, Hu WY, Teng J, Chikara S, Nakayama M, Kishioka H, Kanmatsuse K. Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 2002, 163:229-239. 10.1016/S0021-9150(02)00014-X, 12052469.
41. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999, 452:277-282. 10.1016/S0014-5793(99)00624-9, 10386606.
42. Suganuma E, Babaev VR, Motojima M, Zuo Y, Ayabe N, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 2007, 18:2311-2319. 10.1681/ASN.2006090967, 17634441.
43. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004, 110:3849-3857. 10.1161/01.CIR.0000150540.54220.C4, 15596561.
44. Batenburg WW, Tom B, Schuijt MP, Danser AH. Angiotensin II type 2 receptor -mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor (s). Vascul Pharmacol 2005, 42:109-118. 10.1016/j.vph.2005.01.005, 15792928.
45. Cosentino F, Savoia C, De Paolis P, Francia P, Russo A, Maffei A, Venturelli V, Schiavoni M, Lembo G, Volpe M. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 2005, 18:493-499. 10.1016/j.amjhyper.2004.11.007, 15831358.
46. Carey RM, Park J. Role of angiotensin type 2 receptors in vasodilation of resistance and capacitance vessels. Hypertension 2006, 48:824-825. 10.1161/01.HYP.0000244109.55948.bc, 17015780.
47. Stoll M, Steckelings UM, Paul M. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995, 95:651-657. 10.1172/JCI117710, 295531, 7860748.
48. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001, 134:865-870. 10.1038/sj.bjp.0704331, 1573019, 11606327.
49. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min LJ, Mogi M, Horiuchi M. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005, 112:1636-1643. 10.1161/CIRCULATIONAHA.104.525550, 16145000.
50. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, Sato K, Taniyama Y, Ito S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor- gamma in vascular smooth muscle cells. Endocrinology 2001, 142:3125-3134. 10.1210/en.142.7.3125, 11416035.